Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SL650472, Clopidogrel · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SL650472, Clopidogrel | DRUG | - |
Inclusion Criteria: * 1\. Patient with stable symptoms of intermittent claudication of the lower extremities, secondary to chronic occlusive arterial disease from atherosclerosis origin (symptoms present for 6 months or longer and not significantly changed within the past 3 months); * 2\. ICD of 30...
SL650472 is an investigational small molecule being studied for the treatment of intermittent claudication, a condition characterized by leg pain due to inadequate blood flow during exercise. It is currently in Phase 2 clinical development.
SL650472 is being developed by Sanofi, a multinational pharmaceutical company. Sanofi's stock is traded under the ticker symbol SNY.
SL650472 is in Phase 2 clinical development. It has completed one Phase 2 trial, which was a randomized, double-blind study. The drug is investigational and has not been approved by regulatory authorities.
SL650472 has one completed clinical trial registered under NCT00300339, titled "Mixed Antagonist of Serotonin for Claudication Optimal Therapy." This Phase 2 study enrolled 599 participants with intermittent claudication across multiple countries.
Yes, SL650472 is also known as Clopidogrel. This alternative name may be used in medical literature and clinical contexts, and both names refer to the same investigational drug.